HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.

AbstractPURPOSE:
The pharmacokinetics, pharmacodynamics, efficacy, toxicity, and place in therapy of nivolumab, a novel immunotherapy agent for the treatment of advanced non-small-cell lung cancer (NSCLC) of the squamous cell subtype are reviewed.
SUMMARY:
Nivolumab is a novel programmed cell death 1 (PD-1) immune checkpoint inhibitor indicated as a second-line treatment for patients with NSCLC whose tumors exhibit squamous cell histology. Nivolumab has high affinity for the PD-1 receptor, and durable responses to treatment have been reported in clinical trials. In a Phase II study evaluating the drug's safety and efficacy in patients who had disease progression despite treatment with platinum-based doublet chemotherapy and at least one additional systemic therapy, nivolumab-treated patients had an objective response rate of 14.5%, with a 17% rate of grade 3 or 4 treatment-related adverse events; overall survival at one year was 40.8%. A head-to-head comparison of docetaxel and nivolumab for second-line treatment of squamous cell NSCLC demonstrated superior overall survival and reduced grade 3 or 4 adverse effects in nivolumab-treated patients.
CONCLUSION:
Nivolumab is a novel PD-1 immune checkpoint inhibitor that is effective for treating advanced squamous NSCLC in patients previously treated with platinum-based doublet chemotherapy or alternative first-line agents. Based on its improved efficacy and lower toxicity relative to docetaxel, nivolumab should be considered standard second-line therapy for this population.
AuthorsAmanda Rounds, Jill Kolesar
JournalAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (Am J Health Syst Pharm) Vol. 72 Issue 21 Pg. 1851-5 (Nov 01 2015) ISSN: 1535-2900 [Electronic] England
PMID26490818 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab
Topics
  • Antibodies, Monoclonal (economics, therapeutic use)
  • Antineoplastic Agents (economics, therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy)
  • Carcinoma, Squamous Cell (drug therapy)
  • Clinical Trials as Topic
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Lung Neoplasms (drug therapy)
  • Nivolumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: